<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04861064</url>
  </required_header>
  <id_info>
    <org_study_id>00106369</org_study_id>
    <nct_id>NCT04861064</nct_id>
  </id_info>
  <brief_title>Weekly Sirolimus Therapy</brief_title>
  <official_title>Weekly Sirolimus Therapy for the Treatment of Venous and Lymphatic Malformations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In current practice, options for venous and lymphatic malformations remain limited. Recently&#xD;
      an oral medication, sirolimus, has been found to benefit patients when taken once or twice a&#xD;
      day for several months. Unfortunately there are many side effects associated with this&#xD;
      medication, some of which can be severe including, neutropenia, oral ulcerations, and lab&#xD;
      abnormalities. The purpose of this study is to determine if once weekly dosed sirolimus will&#xD;
      be effective for the treatment of venous and lymphatic malformations. Additionally, the study&#xD;
      will evaluate patient satisfaction and identify adverse effects. Participants will be on the&#xD;
      medication for 6 months with an option to continue after this time period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 18, 2021</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in size of lesion</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Will be measuring the size of the lesions (mm) at each patient visit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in size of lesion through photograph</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Will be evaluating clinical photographs of lesions at each patient visit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of side effects experienced</measure>
    <time_frame>Month One</time_frame>
    <description>Patient will complete side effect questionnaires at each visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of side effects experienced</measure>
    <time_frame>Month Two</time_frame>
    <description>Patient will complete side effect questionnaires at each visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of side effects experienced</measure>
    <time_frame>Month Three</time_frame>
    <description>Patient will complete side effect questionnaires at each visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of side effects experienced</measure>
    <time_frame>Month Four</time_frame>
    <description>Patient will complete side effect questionnaires at each visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of side effects experienced</measure>
    <time_frame>Month Five</time_frame>
    <description>Patient will complete side effect questionnaires at each visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of side effects experienced</measure>
    <time_frame>Month Six</time_frame>
    <description>Patient will complete side effect questionnaires at each visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life as assessed by questionnaire</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Patient will complete quality of life questionnaire at each visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with laboratory abnormalities</measure>
    <time_frame>From baseline visit to 2 month visit</time_frame>
    <description>Standard of care laboratory results (CBC, CMP, triglycerides) will be monitored</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Venous Malformation</condition>
  <condition>Lymphatic Malformation</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Participants will get Sirolimus (1.5-2 2mg/m2) weekly for 6 months.</description>
    <arm_group_label>Treatment Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient 2 years of age and older&#xD;
&#xD;
          -  Venous, lymphatic, or venolymphatic malformations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Children with contraindication to use of sirolimus&#xD;
&#xD;
          -  Children with history of transplant&#xD;
&#xD;
          -  Children with a history of natural immunodeficiency&#xD;
&#xD;
          -  Children with a history of artificially induced immunodeficiency&#xD;
&#xD;
          -  Children with a history of a serious or life-threatening infection&#xD;
&#xD;
          -  Children taking CYP3A4 inhibiting medications&#xD;
&#xD;
          -  Children taking strong CYP3A4 inducers to avoid subtherapeutic dosing/exposure.&#xD;
&#xD;
          -  Inability or unwillingness of subject or legal guardian/representative to give&#xD;
             informed consent&#xD;
&#xD;
          -  Women that are or may become pregnant o Sirolimus is a Pregnancy Category C drug. No&#xD;
             randomized controlled studies have been done on pregnant women. Women of childbearing&#xD;
             potential must be on effective contraception prior to, during, and for 12 weeks&#xD;
             following sirolimus therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandra Ritter, BS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexandra Ritter, BS</last_name>
    <phone>843-876-3209</phone>
    <email>ritteral@musc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra M Ritter</last_name>
      <phone>843-792-9784</phone>
      <email>ritteral@musc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 23, 2021</study_first_submitted>
  <study_first_submitted_qc>April 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2021</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of South Carolina</investigator_affiliation>
    <investigator_full_name>Alexandra Ritter</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphangioma</mesh_term>
    <mesh_term>Lymphatic Abnormalities</mesh_term>
    <mesh_term>Congenital Abnormalities</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

